PUBLISHER: TechNavio | PRODUCT CODE: 2144693
PUBLISHER: TechNavio | PRODUCT CODE: 2144693
Global Anterior Uveitis Treatment Market 2026-2030
The global anterior uveitis treatment market is forecasted to grow by USD 140264.6 thousand during 2025-2030, accelerating at a CAGR of 4.5% during the forecast period. The report on the global anterior uveitis treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising global incidence of systemic autoimmune conditions, regulatory support and incentives for orphan ophthalmic drugs, expansion of advanced ophthalmic surgical infrastructure globally.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 4.4% |
| CAGR | 4.5% |
| Incremental Value | $140264.6 thousand |
Technavio's global anterior uveitis treatment market is segmented as below:
By Type
- Medications
- Surgery
By Disease Type
- Infectious uveitis
- Non-infectious uveitis
By Drug Class
- Corticosteroids
- Biologics and Biosimilars
- Others
Geography
- North America
- US
- Canada
- Mexico
- Asia
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the shift toward non steroidal macrophage modulating therapeutics as one of the prime reasons driving the global anterior uveitis treatment market growth during the next few years. Also, development of sustained release intracameral drug delivery and adoption of digital anterior chamber imaging technologies will lead to sizable demand in the market.
The report on the global anterior uveitis treatment market covers the following areas:
- Global anterior uveitis treatment market sizing
- Global anterior uveitis treatment market forecast
- Global anterior uveitis treatment market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global anterior uveitis treatment market vendors that include AbbVie Inc., Amgen Inc., ANI Pharmaceuticals Inc., Apotex Inc., Aurobindo Pharma Ltd., Bausch Lomb Corp., Cadila Pharmaceuticals Ltd., Cipla Inc., Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Hikma Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., Mankind Pharma Ltd., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sandoz Group AG, Santen Pharmaceutical Co. Ltd.. Also, the global anterior uveitis treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by Disease Type
- Executive Summary - Chart on Market Segmentation by Drug Class
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Anterior Uveitis Treatment Market 2020 - 2024
- Historic Market Size - Data Table on Global Anterior Uveitis Treatment Market 2020 - 2024 ($ thousand)
- 5.2 Type segment analysis 2020 - 2024
- Historic Market Size - Type Segment 2020 - 2024 ($ thousand)
- 5.3 Disease Type segment analysis 2020 - 2024
- Historic Market Size - Disease Type Segment 2020 - 2024 ($ thousand)
- 5.4 Drug Class segment analysis 2020 - 2024
- Historic Market Size - Drug Class Segment 2020 - 2024 ($ thousand)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ thousand)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ thousand)
6 Qualitative Analysis
- 6.1 Impact of AI on global anterior uveitis treatment market
- 6.2 Impact of geopolitical conflicts on global anterior uveitis treatment market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Type
- 8.1 Market segments
- 8.2 Comparison by Type
- 8.3 Medications - Market size and forecast 2025-2030
- 8.4 Surgery - Market size and forecast 2025-2030
- 8.5 Market opportunity by Type
- Market opportunity by Type ($ thousand)
9 Market Segmentation by Disease Type
- 9.1 Market segments
- 9.2 Comparison by Disease Type
- 9.3 Infectious uveitis - Market size and forecast 2025-2030
- 9.4 Non-infectious uveitis - Market size and forecast 2025-2030
- 9.5 Market opportunity by Disease Type
- Market opportunity by Disease Type ($ thousand)
10 Market Segmentation by Drug Class
- 10.1 Market segments
- 10.2 Comparison by Drug Class
- 10.3 Corticosteroids - Market size and forecast 2025-2030
- 10.4 Biologics and Biosimilars - Market size and forecast 2025-2030
- 10.5 Others - Market size and forecast 2025-2030
- 10.6 Market opportunity by Drug Class
- Market opportunity by Drug Class ($ thousand)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Asia - Market size and forecast 2025-2030
- 12.4.1 China - Market size and forecast 2025-2030
- 12.4.2 India - Market size and forecast 2025-2030
- 12.4.3 Japan - Market size and forecast 2025-2030
- 12.4.4 South Korea - Market size and forecast 2025-2030
- 12.4.5 Indonesia - Market size and forecast 2025-2030
- 12.4.6 Thailand - Market size and forecast 2025-2030
- 12.5 Europe - Market size and forecast 2025-2030
- 12.5.1 Germany - Market size and forecast 2025-2030
- 12.5.2 UK - Market size and forecast 2025-2030
- 12.5.3 France - Market size and forecast 2025-2030
- 12.5.4 Italy - Market size and forecast 2025-2030
- 12.5.5 Spain - Market size and forecast 2025-2030
- 12.5.6 The Netherlands - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.3 UAE - Market size and forecast 2025-2030
- 12.6.4 Turkey - Market size and forecast 2025-2030
- 12.6.5 Argentina - Market size and forecast 2025-2030
- 12.6.6 Colombia - Market size and forecast 2025-2030
- 12.6.7 South Africa - Market size and forecast 2025-2030
- 12.6.8 Israel - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ thousand)
- Data Tables on Market opportunity by geography ($ thousand)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Rising global incidence of systemic autoimmune conditions
- Regulatory support and incentives for orphan ophthalmic drugs
- Expansion of advanced ophthalmic surgical infrastructure globally
- 13.2 Market challenges
- Steroid induced ocular complications and adverse safety profiles
- Patient non compliance and topical administration complexities
- High economic burden of advanced biologic interventions
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Shift toward non steroidal macrophage modulating therapeutics
- Development of sustained release intracameral drug delivery
- Adoption of digital anterior chamber imaging technologies
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 AbbVie Inc.
- AbbVie Inc. - Overview
- AbbVie Inc. - Business segments
- AbbVie Inc. - Key news
- AbbVie Inc. - Key offerings
- AbbVie Inc. - Segment focus
- SWOT
- 15.5 Amgen Inc.
- Amgen Inc. - Overview
- Amgen Inc. - Product / Service
- Amgen Inc. - Key news
- Amgen Inc. - Key offerings
- SWOT
- 15.6 ANI Pharmaceuticals Inc.
- ANI Pharmaceuticals Inc. - Overview
- ANI Pharmaceuticals Inc. - Product / Service
- ANI Pharmaceuticals Inc. - Key offerings
- SWOT
- 15.7 Bausch Lomb Corp.
- Bausch Lomb Corp. - Overview
- Bausch Lomb Corp. - Business segments
- Bausch Lomb Corp. - Key news
- Bausch Lomb Corp. - Key offerings
- Bausch Lomb Corp. - Segment focus
- SWOT
- 15.8 Cadila Pharmaceuticals Ltd.
- Cadila Pharmaceuticals Ltd. - Overview
- Cadila Pharmaceuticals Ltd. - Product / Service
- Cadila Pharmaceuticals Ltd. - Key offerings
- SWOT
- 15.9 Dr. Reddys Laboratories Ltd.
- Dr. Reddys Laboratories Ltd. - Overview
- Dr. Reddys Laboratories Ltd. - Business segments
- Dr. Reddys Laboratories Ltd. - Key news
- Dr. Reddys Laboratories Ltd. - Key offerings
- Dr. Reddys Laboratories Ltd. - Segment focus
- SWOT
- 15.10 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 15.11 Hikma Pharmaceuticals Plc
- Hikma Pharmaceuticals Plc - Overview
- Hikma Pharmaceuticals Plc - Business segments
- Hikma Pharmaceuticals Plc - Key news
- Hikma Pharmaceuticals Plc - Key offerings
- Hikma Pharmaceuticals Plc - Segment focus
- SWOT
- 15.12 Johnson and Johnson
- Johnson and Johnson - Overview
- Johnson and Johnson - Business segments
- Johnson and Johnson - Key news
- Johnson and Johnson - Key offerings
- Johnson and Johnson - Segment focus
- SWOT
- 15.13 Lupin Ltd.
- Lupin Ltd. - Overview
- Lupin Ltd. - Business segments
- Lupin Ltd. - Key news
- Lupin Ltd. - Key offerings
- Lupin Ltd. - Segment focus
- SWOT
- 15.14 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 15.15 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Segment focus
- SWOT
- 15.16 Regeneron Pharmaceuticals Inc.
- Regeneron Pharmaceuticals Inc. - Overview
- Regeneron Pharmaceuticals Inc. - Product / Service
- Regeneron Pharmaceuticals Inc. - Key news
- Regeneron Pharmaceuticals Inc. - Key offerings
- SWOT
- 15.17 Sandoz Group AG
- Sandoz Group AG - Overview
- Sandoz Group AG - Business segments
- Sandoz Group AG - Key news
- Sandoz Group AG - Key offerings
- Sandoz Group AG - Segment focus
- SWOT
- 15.18 Santen Pharmaceutical Co. Ltd.
- Santen Pharmaceutical Co. Ltd. - Overview
- Santen Pharmaceutical Co. Ltd. - Product / Service
- Santen Pharmaceutical Co. Ltd. - Key offerings
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
